PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow -1.9% ·
net new positions -18.2%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 18.67K | $1.18M | n/a | −1 |
| Q2 2026 | 113 | +8 | 59.00M | $4.80B | +13 | −7 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | n/a |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | n/a |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | n/a |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | n/a | n/a |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.28M | $436.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.89M | -3.9% | $292.82M | 0.1% | ▼ Trim | 2 | SEC ↗ ×7 |
| 2 | Geode Capital Management ✦ (passive) | 1.80M | +0.6% | $66.74M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | D. E. Shaw & Co. ✦ | 1.42M | +4.6% | $52.66M | 0.1% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | Point72 Asset Management ✦ | 575.86K | +2056.8% | $21.36M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 559.75K | -7.7% | $20.77M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 538.20K | -34.2% | $19.97M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 317.30K | -0.3% | $11.77M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 250.00K | -16.7% | $9.28M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 239.13K | -11.5% | $8.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Millennium Management ✦ | 219.46K | -30.9% | $8.14M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 189.58K | +175.1% | $7.03M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $5.49M | was 0.0% |
| Norges Bank | $461,758 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 348 holders, 95.15M shares, $6.33B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 382 sh · $22,973
Director · 2.12K sh · $126,063
Officer · 192 sh · $12,338
Director · 2.45K sh · $155,091
Director · 53 sh · $3,389
Officer · 435 sh · $27,910
Officer · 1.64K sh · $104,881
Director · 376 sh · $25,737
Director · 9.62K sh · $652,796
Director · 7.01K sh · $471,854
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology